文献速递消化、代谢与肾脏急症

急诊科急性疼痛治疗中三种单剂静脉酮咯酸方案的比较:一项随机对照试验

Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial.
PubMed 文献 · Ann Emerg Med · 2016-12-16
一句话结论急诊中度至重度急性疼痛患者中,静脉酮咯酸10 mg与15 mg、30 mg的30分钟镇痛效果相似,不良事件无显著差异。

本研究为随机双盲试验,纳入240例急诊中度至重度急性疼痛患者(数字评定量表评分≥5分),随机接受静脉酮咯酸10 mg、15 mg或30 mg(每组80例)。主要终点为30分钟疼痛减轻程度,三组间无差异(95%CI分别为10 mg组4.5至5.7、15 mg组4.5至5.6、30 mg组4.2至5.4)。基线平均数字评定量表评分分别为7.7、7.5、7.8,30分钟时分别改善至5.1、5.0、4.8。补救镇痛率相似,无严重不良事件;最常见不良事件为头晕、恶心和头痛。结论认为静脉酮咯酸10 mg(镇痛天花板剂量)即可有效缓解急诊中度至重度疼痛,且不增加不良事件。

要点

  • 急诊中度至重度急性疼痛(数字评定量表评分≥5分)患者,静脉酮咯酸10 mg、15 mg、30 mg在30分钟时的疼痛减轻程度无差异(95%CI分别为4.5至5.7、4.5至5.6、4.2至5.4)。
  • 三组基线平均数字评定量表评分分别为7.7、7.5、7.8,30分钟时分别改善至5.1、5.0、4.8。
  • 三组补救镇痛率相似,无严重不良事件;最常见不良事件为头晕、恶心和头痛,各组发生率相似。
  • 静脉酮咯酸10 mg(镇痛天花板剂量)可为急诊中度至重度疼痛患者提供有效镇痛,且不增加不良事件。

适用人群与场景

  • 年龄18至65岁、因中度至重度急性疼痛就诊于急诊科的患者,疼痛定义为数字评定量表评分大于或等于5分。
  • 排除消化性溃疡病、消化道出血、肾或肝功能不全、非甾体抗炎药过敏、妊娠或哺乳期、收缩压小于90或大于180 mm Hg、脉率小于50或大于150次/分的患者。

诊断标准与关键阈值

  • 急性疼痛程度采用数字评定量表评估,纳入标准为评分大于或等于5分。

处置流程与药物剂量

  • 静脉给予酮咯酸10 mg、15 mg或30 mg单剂(研究方案分组)。
  • 给药后30分钟若受试者仍需要额外镇痛药物,给予静脉吗啡0.1 mg/kg作为补救镇痛。
  • 记录基线和至120分钟的疼痛评分。

研究设计与关键结果

  • 随机双盲试验纳入240例急诊中度至重度急性疼痛患者,每组80例,分别接受静脉酮咯酸10 mg、15 mg或30 mg。
  • 主要终点30分钟疼痛减轻程度三组间无差异,95%CI分别为10 mg组4.5至5.7、15 mg组4.5至5.6、30 mg组4.2至5.4。
  • 基线平均数字评定量表评分分别为10 mg组7.7、15 mg组7.5、30 mg组7.8,30分钟时分别改善至5.1、5.0、4.8。
  • 补救镇痛率三组相似,无严重不良事件;各组不良事件发生率相似,最常见为头晕、恶心和头痛。

证据类型、等级与局限

  • 证据类型:随机双盲对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为静脉酮咯酸10 mg(镇痛天花板剂量)可为急诊中度至重度疼痛患者提供有效镇痛,且不增加不良事件。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: Nonsteroidal anti-inflammatory drugs are used extensively for the management of acute and chronic pain, with ketorolac tromethamine being one of the most frequently used parenteral analgesics in the emergency department (ED). The drugs may commonly be used at doses above their analgesic ceiling, offering no incremental analgesic advantage while potentially adding risk of harm. We evaluate the analgesic efficacy of 3 doses of intravenous ketorolac in ED patients with acute pain.

METHODS: We conducted a randomized, double-blind trial to assess the analgesic efficacy of 3 doses of intravenous ketorolac (10, 15, and 30 mg) in patients aged 18 to 65 years and presenting to the ED with moderate to severe acute pain, defined by a numeric rating scale score greater than or equal to 5. We excluded patients with peptic ulcer disease, gastrointestinal hemorrhage, renal or hepatic insufficiency, allergies to nonsteroidal anti-inflammatory drugs, pregnancy or breastfeeding, systolic blood pressure less than 90 or greater than 180 mm Hg, and pulse rate less than 50 or greater than 150 beats/min. Primary outcome was pain reduction at 30 minutes. We recorded pain scores at baseline and up to 120 minutes. Intravenous morphine 0.1 mg/kg was administered as a rescue analgesic if subjects still desired additional pain medication at 30 minutes after the study drug was administered. Data analyses included mixed-model regression and ANOVA.

RESULTS: We enrolled 240 subjects (80 in each dose group). At 30 minutes, substantial pain reduction was demonstrated without any differences between the groups (95% confidence intervals 4.5 to 5.7 for the 10-mg group, 4.5 to 5.6 for the 15-mg group, and 4.2 to 5.4 for the 30-mg group). The mean numeric rating scale pain scores at baseline were 7.7, 7.5, and 7.8 and improved to 5.1, 5.0, and 4.8, respectively, at 30 minutes. Rates of rescue analgesia were similar, and there were no serious adverse events. Secondary outcomes showed similar rates of adverse effects per group, of which the most common were dizziness, nausea, and headache.

CONCLUSION: Ketorolac has similar analgesic efficacy at intravenous doses of 10, 15, and 30 mg, showing that intravenous ketorolac administered at the analgesic ceiling dose (10 mg) provided effective pain relief to ED patients with moderate to severe pain without increased adverse effects.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Motov S, Yasavolian M, Likourezos A, et al. Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2016. PMID: 27993418. doi:10.1016/j.annemergmed.2016.10.014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。